Regulated expression of therapeutic genes is required for long-term gene therapy applications for many disorders. Here we describe a doxycycline (dox)-regulated lentiviral vector system consisting of two HIV-1-based self-inactivating viruses. One of the vectors is constitutively expressing a novel improved version of the tetracycline reverse transactivator rtTA2
Introduction
Gene therapy applications with the aim of long-term expression of the treatment gene impose several demands on gene transfer vectors. In addition to efficient and stable delivery, there is a clear need for regulated expression of the transgene. For safe treatments, it may be necessary to maintain protein concentrations within a therapeutic window. Gene expression should be regulated in a dose-dependent way by an orally available, well-tolerated drug, and induction and repression of the gene expression should be reversible. 1 The most widely studied systems for gene regulation in eukaryotic cells are Tet-off 2 and Tet-on 3 systems based on E.coli tetracycline (Tc) resistance operon. 4 In E.coli, the repressor protein of the operon binds to its operator (tetO) sequence with a high specificity. The interaction between the repressor and the operator is prevented by tetracycline and its derivative doxycycline (dox). The Teton system used in mammalian cells relies on the specific binding of a chimeric transcriptional factor, reversetetracycline-transactivator (rtTA), on its target promoter in the presence of dox. The target promoter consists of an array of tetO-sequences fused upstream of a minimal promoter. The transactivator is a fusion protein of the repressor protein mutated to have reverse binding properties as compared to the original repressor and transcription activator (C-terminal domain of the VP16 protein of the herpes simplex virus).
However, despite many useful applications, the original Tet-on system has some limitations caused by properties of the rtTA. The most important limitation is a residual affinity of the rtTA to tetO in the absence of dox, which has led to increased background activity. Leaking of the promoter is not desirable especially with therapeutic proteins which are effective at low doses, eg growth factors. Also, relatively inefficient inducibility by dox via the rtTA in some organs, eg brain, and instability of the rtTA have limited the use of the Tet-on system. 5 The recently described mutated reverse transactivator rtTA2 S -M2 6 has highly improved properties with respect to specificity, stability and inducibility. It functions at 10-fold lower dox concentration than the original rtTA, is more stable in eukaryotic cells and most importantly, causes no background expression in the absence of dox. The rtTA2 S -M2 was generated by random mutagenesis of the tetracycline repressor gene and screening for alleles with reverse binding properties. The VP16 activation domain was replaced with a minimal activation domain consisting of 12 amino acids 7 and a coding sequence optimized for expression in human cells.
Lentiviral vectors such as HIV-1-derived vectors are promising tools for gene therapy applications demanding long-term expression. They integrate into host genome and can transduce both dividing and non-dividing cells. Here, we describe a dox-regulated lentiviral vector system consisting of two HIV-1-based viruses pseudotyped with vesicular stomatitis virus G glycoprotein (VSV-G). HIV-vectors of the system are selfinactivating (SIN) to minimize the risk of the promoter interference due to viral LTRs and to reduce the risk of the appearance of replication-competent recombinant viruses. 8 Also, the biosafety of the vector system has been improved with a minimal packaging system 9 which has only three of the nine native HIV-1 genes left in two separate packaging plasmids. As a reverse transactivator we have used the novel improved rtTA2 S -M2. It was found that the expression system was functional in vitro and in vivo when delivered with two lentiviral vectors. The vector system also had a tight control of the gene expression over a broad range of regulation.
Results

Functionality of the doxycycline-regulated HIV-vector system
As a backbone for the cloning of HIV/ rtTA2 S -M2 and HIV/TRE/LZ vectors (Figure 1 ), SIN-vector was used. 
Dose-response for doxycycline
Dose-response of the regulated vector system for dox was studied in cotransduced CHO cells (Figure 3 ). Cotransduced cells were exposed to increasing concentrations of dox in culture medium (0, 5, 50, 500 and 1000 ng/ml). Results are presented as relative light units/mg of protein. Without dox b-galactosidase activity was at or below the detection level. Induction of lacZ expression was seen with dox concentration of 5 ng/ml and full induction was achieved with 500 ng/ml.
On/off switching of b-galactosidase expression in longterm cultures Cotransduced CHO cells were exposed to dox (500 ng/ ml) three times to switch the expression of lacZ on/off during long-term cultures ( Figure 4 ). The first induction 2 days after the cotransduction resulted in a high bgalactosidase activity. After day 4 dox was withdrawn. Rapid loss of the b-galactosidase activity was not expected because of the stability of the b-galactosidase enzyme in cell culture, but at day 6 the activity had returned to the background level. Nine days and three cell passages after the cotransduction dox was added for the second time, and a clear induction of b-galactosidase activity was found. After the second induction dox was withdrawn and cells were cultured until day 79 (13 cell passages after cotransduction) when b-galactosidase activity was measured and found to be at the background level. The third induction resulted in a similar increase in the b-galactosidase activity as detected during the second induction.
RT-PCR and genomic PCR of cell samples
To achieve maximal sensitivity of RT-PCR, nested PCR was used to study lacZ expression of the cotransduced CHO cells in the presence or absence of dox (Figure 5a ). Signal was detected from cells cultured with dox, whereas no signal was detected from cells cultured without dox. However, genomic PCR showed the presence of vector DNA in both induced and noninduced cells (Figure 5b ).
Analysis of rat brain tissue with PCR, RT-PCR and Xgal staining
In all cotransduced rats, PCR-analysis of brain DNA 10 days after the gene transfer confirmed that transduction had succeeded with both HIV/TRE/LZ and HIV/ rtTA2 S -M2 vectors ( Figure 6a and b). Also, RT-PCR for rtTA2 S -M2 proved that the reverse transactivator was expressed in every animal ( Figure 6c ). RT-PCR for LacZ showed no signal in the brains of rats which were not treated with dox (n¼3), whereas five of the seven doxtreated (1 mg for 4 days) rats showed a signal in brain indicating that the expression of LacZ was dependent for dox ( Figure 6d ). With X-gal staining single-positive cells were observed in sections of the dox-treated animals, but no positive cells were found in the control animals ( Figure 7 ).
Discussion
HIV-1-derived lentiviral vectors are attractive tools for gene therapy because of their ability to integrate into the chromatin of both dividing and non-dividing cells. Lentiviral vectors have been shown to deliver genes in Figure 3 Doxycycline dose-response of the system was determined in cotransduced CHO cells. Doxycycline was added at concentrations 0, 5, 50, 500 and 1000 ng/ml (n¼4 for each group) 2 days after cotransduction. b-galactosidase activity (mean7s.e.m) of the cell samples was studied 22 h after induction. 22 and kidney. 23 Moreover, the biosafety of HIV-1-based vectors has been highly improved with modifications to vectors and minimal packaging systems. 9 In our vector system, the elements required for regulated expression are located in two separate HIVderived vectors and cotransduction of the target cells with both vectors is required. In vitro, cotransduction efficiency was 30-50% (data not shown) which is in line with results reported by Frimpong and Spector 24 who demonstrated successful cotransfection of both dividing and non-dividing cells with two VSV-G pseudotyped HIV-1 vectors. It was reported that the cotransduction efficiency with two separate vectors was directly proportional to the individual transduction efficiencies obtained with single vectors suggesting the absence of viral interference.
Several systems for the regulation of transgene expression by exogenous drugs have been developed.
3,25-28 Some major advantages of the Tet-on system compared to the other gene regulation systems are a well-known safety profile, easy availability and good tissue penetration of the regulating drug dox. Bacterial origin of the Tet-on elements assures minimal interference with endogenous physiological processes of the eukaryotic cells. Nevertheless, the major drawback of the system has been the residual affinity of the rtTA to its operator in the absence of dox which has led to significant background expression. The use of the novel mutated reverse transactivator rtTA2 S -M2 abolishes the background expression and already greatly enhances the potential of the system. Our results support the expected tight control of the gene expression since in the absence of dox b-galactosidase activity was at or below the detection level and no lacZ mRNA was detected with nested RT-PCR in the cell culture experiments. The system was also responding to dox over a broad concentration range (5-500 ng/ml) suggesting that the level of the therapeutic protein could be finely adjusted with dox concentrations which can be achieved in vivo by oral administration (2-3 mg/ml in serum with 200 mg of dox). The long-term cell culture experiments of the cotransduced cells with several on/off dox cycles confirmed the ability to regulate gene expression in actively dividing, non-selected cells over a prolonged time.
Lentiviral vectors are known to mediate efficient in vivo gene delivery to central nervous system. 10, 29 Therefore, rat brain was chosen as target tissue for testing the proof of principle of the vector system in vivo. PCR showed that the transduction of brain was successful with both vectors. RT-PCR confirmed that the tightness of the expression control was also achieved in vivo.
Recently, two reports on the successful use of novel mutated versions of the tetracycline-dependent transcriptional activators 6 have been published. Vigna et al 30 used Tet-off application with a tetracycline transactivator S -S2 in their plasmid vector system. They reported a stringent control of the mouse erythropoietin expression and hematocrit levels over a 10-month period after injection of the plasmids containing rtTA2 S -S2 expression cassette and the Tet-responsive mEpo cDNA in mouse quadriceps muscles by DNA electroinjections. They also reported remarkably lower background expression in the absence of dox with both rtTA2 S -M2 and rtTA2 S -S2 as compared to the original rtTA in vivo.
Our study demonstrates that the elements needed for dox-regulated gene expression can be delivered in vivo with HIV-vectors. The system should be useful for longterm gene therapy applications.
Materials and methods
Construction of HIV-based vectors
Dox-regulated vector system consists of two HIV-1-based vectors ( Figure 1 ). HIV/rtTA2 S -M2 is for constitutive expression of the reverse transactivator. Target vector HIV/TRE/LZ consists of the lacZ marker gene coding for E.coli b-galactosidase under the minimal cytomegalovirus (CMV) promoter fused to Tet-responsible element (TRE). TRE has seven copies of the 42 bp tetO sequences.
As a backbone for the HIV-vector plasmids, the HIV-CS plasmid 8 kindly provided by Dr Inder Verma was used. In HIV-CS, the U3 region of the 5 0 LTR is replaced with a CMV promoter resulting in Tat-independent transcription. Also, in U3 of the 3 0 LTR a 133 bp region containing promoter and enhancer sequences is deleted leading to a self-inactivating (SIN) vector. S -M2 vector plasmid, XhoI-BamHI fragment of pUHrT61-1 6 consisting of hCMV promoter and cDNA of rtTA2 S -M2 was blunted and inserted into Eco47III site of the HIV-CS plasmid. For the construction of HIV/TRE/LZ LacZ cDNA fragment was inserted between HindIII and XbaI sites of the pTRE2 plasmid (Clontech, Palo Alto, CA, USA). pTRE2/LacZ was digested with XhoI and a fragment with TRE/CMV-promoter and LacZ cDNA was inserted into XhoI site of the HIV-CS.
Preparation of viral stocks
VSV-G pseudotyped HIV vectors were generated by transient cotransfection of vector plasmid (20 mg), VSV-G expressing construct pCMV-G (7 mg) and packaging constructs 9 pMDLg/pRRE (13 mg) and pRSV-Rev (5 mg) with FuGENE TM 6 reagent (Roche, Indianapolis, IN, USA) into 293T cells on 15 cm tissue culture plates. Four hours prior to transfection fresh growth medium (15 ml) was added to 60-80% confluent cells. Four plasmids were mixed and solution added dropwise to the FuGENE reagent (67.5 ml diluted with cell culture media to 500 ml per plate). After 15 min incubation at room temperature transfection mix was added to cells. Fresh growth medium was changed 20-24 h after cotransfection. Conditioned medium was collected 48, 72 and 96 h after cotransfection, sterile filtered with Steriflip Filter Units (Millipore), frozen on dry ice and stored at À80 o C until concentration. Viral stocks were concentrated by ultracentrifugation of conditioned medium at 50 000 g at 41C for 2 h. Pellets were resuspended in 0.1 Â Hanks'/1% sucrose in PBS at 1/100 of the original volume. The titers of lentiviral vectors were determined by measuring the amount of HIV p24 Gag antigen by ELISA (Alliance; NEN Life Science Products, Boston, MA, USA). As a reference virus for titer determination GFP expressing HIV-vector titered with flow cytometry was used. Titers obtained with ELISA were converted to transducing units/ml (TU/ml) based on the assumption that the frequency of functional virus particle production is essentially the same for all preparations. Routinely, 1 Â 10 4 transducing units/ng of p24 gag protein was observed.
Testing the functionality of doxycycline-regulated HIVvector system
Functionality of the vector system was tested in CHO cell line and in human endothelial hybridoma cell line (EAhy926 provided by Dr Edgell, University of North Carolina, NC, USA). Cells were seeded in 12-well cell culture plates at the density of 7 Â 10 4 cells/cm 2 . One day after seeding, fresh culture medium with 8 mg/ml of Polybrene was changed. For cotransduction of CHO cells, HIV-vectors were added at final virus concentration of 3 Â 10 6 TU/ml of medium at concentration ratio of 1:2 of HIV/TRE/LZ to HIV/ rtTA2 S -M2 producing total multiplicity of infection (MOI) of 3 per cell. Also, a transduction with HIV/TRE/LZ alone was performed. EAhy926 cells were cotransduced with two different final virus concentrations: 3 Â 10 6 and 9 Â 10 6 TU/ml producing total MOIs of 3 and 9, respectively. On the following day, fresh culture medium was added and induction started with dox concentration of 1 mg/ml (n¼4). For non-induced cells dox was not added (n¼4). For studying dox dose-response CHO-cells were cotransduced in 60 mm tissue culture plate with final virus concentration of 3 Â 10 6 TU/ml producing total MOI of 3. Concentration ratio of HIV/TRE/LZ to HIV/ rtTA2 S -M2 was 1:2. One day after cotransduction cells were washed with PBS and split into 24-well cell culture plates. Two days after cotransduction dox was added at concentrations 0, 5, 50, 500 and 1000 ng/ml (n¼4 for each group). b-galactosidase activity of the cell samples was studied 22 h after induction as described above.
Switching b-galactosidase expression on/off
To test whether the expression of b-galactosidase could be switched on/off CHO cells were cotransduced similarly as in dox dose-response study. One day after the cotransduction cells were split into 24-well cell culture plate. Two days after the cotransduction, basal b-galactosidase activity was measured and induction with dox (500 ng/ml) started. After 4 days, dox was withdrawn. b-Galactosidase activity was determined daily from three wells. Nine days after the cotransduction dox was added for the second time and after 12 days, withdrawn again. Cells were cultured normally without dox in the medium. On day 79 (13 cell passages after the cotransduction) b-galactosidase activity was determined and cells exposed to dox for the third time. Third induction was studied by measuring b-galactosidase activity on days 80-82.
PCR and RT-PCR of cell samples
Cell samples were analyzed for LacZ expression with RT-PCR and for the presence of lacZ gene in genome with genomic PCR. CHO cells were cotransduced as described with dox dose-response study. Two days after cotransduction cells were trypsinized and split into two 10 cm plates and induction with 1 mg/ml of dox for the other plate was started 1 day after splitting. Two days after the beginning of the induction total RNA and DNA were extracted using Trizol Reagent (Gibco BRL) according to the manufacturer's instructions.
Total RNA was treated with DNaseI (Promega) to remove any contaminating DNA and cDNA synthesis was performed with 2 mg of RNA with random hexamers. Nested PCR was used for RT-PCR to get maximal sensitivity. Primers for the first amplification were forward: DNA polymerase (Applied Biosystems). PCR amplifications were carried out using the following conditions: the first denaturation step at 951C for 10 min, followed by 40 cycles with 45 s at 951C, 45 s at 581C, 45 s at 721C with the final step at 721C for 15 min. For the second PCR, 10 ml of the first amplification mix was used with similar cycling parameters as for the first PCR (40 cycles).For genomic PCR 500 ng of DNA was used. The same primer pair was used as for the second amplification in RT-PCR with similar PCR mixture contents and cycling parameters (30 cycles).
Cotransduction of rat brain with intracranial injection
Inbred female Wistar rats (M&B A/S, Ry, Denmark) were used for the study (n¼20). Rats (150-200 g) were anesthesized with a mixture (0.150 ml/kg) of fentanylfluonisone (Hypnorm: Janssen, Beerse, Belgium) and midazolam (Dormicum: Roche, Basel, Switzerland), placed into stereotactic apparatus (Kopf Instruments, Germany), and a burr hole was drilled 0.7 mm anterior to bregma and 1.8 mm lateral to sagittal sutura, dura was incised with a 27 gauge needle. Viruses were diluted to 0.1 Â Hanks'/1% sucrose in PBS, mixed and injected through a 25 ml Hamilton syringe (Hamilton Bonaduz AG, Switzerland) with a 27 gauge needle to just approximate to right putamen of the corpus striatum. Injections (20 ml) were done 4.5 and 4.0 mm ventrally from the dura mater and repeated a day after. Animals received a total dose of 8 Â 10 5 TU of vectors in a ratio of 1:2 of HIV/TRE/LZ to HIV/rtTA2 S -M2. Six days after the cotransduction dox induction was started in 14 rats with a daily ip injection of dox (1 mg). Ten days after the cotransduction the rats were sacrified. Brain samples of 10 rats (seven +dox rats, three without dox) were frozen in liquid nitrogen for PCR and RT-PCR analysis. The brains of 10 rats (seven +dox rats, three without dox) were fixed in 4% paraformaldehyde/ 0.15 M sodium phosphate buffer for 30 min, rinsed with 0.15 M sodium phosphate buffer for 2 h, embedded in OCT compound (Miles Scientific, Naperville, IL, USA) and whole brain was processed for frozen sections. The sections were stained with X-gal for b-galactosidase activity. The X-gal reagent (5-bromo-4-chloro-3-indolylb-D-galactoside) (MBI Fermentas, Lithuania) was diluted 1:100 with X-gal solution (5 mM K 3 Fe(CN) 6 , 5 mM K 4 Fe(CN) 6 , 2 mM MgCl 2 ) added on the sections and incubated for 16 h at 371C. Sections were rinsed with phosphate-buffered saline and counterstained with Mayer's Carmalum. 32 Micrographs were taken by Olympus AX 70 microscope (Olympus Optical, Tokyo, Japan).
RNA and DNA extractions, DNase I treatment, cDNAse synthesis, lacZ PCR and RT-PCR of rat brain samples near the injection site were performed similarly as for the cell samples. Primers used for rtTA2 S -M2 PCR and RT-PCR were forward: 5 0 -GAGCAAAGTCA-TAAACGGCGC-3 0 and reverse: 5 0 -CGCGATGTGAGAG-GAGAGCA-3 0 producing a 267 bp PCR-product. Similar reaction conditions and cycling parameters were used as for lacZ PCR.
